JP2013537418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013537418A5 JP2013537418A5 JP2013524306A JP2013524306A JP2013537418A5 JP 2013537418 A5 JP2013537418 A5 JP 2013537418A5 JP 2013524306 A JP2013524306 A JP 2013524306A JP 2013524306 A JP2013524306 A JP 2013524306A JP 2013537418 A5 JP2013537418 A5 JP 2013537418A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- heavy chain
- amino acid
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 102000015696 Interleukins Human genes 0.000 claims description 6
- 108010063738 Interleukins Proteins 0.000 claims description 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37448910P | 2010-08-17 | 2010-08-17 | |
| US61/374,489 | 2010-08-17 | ||
| PCT/AU2011/000155 WO2011100786A1 (en) | 2010-02-17 | 2011-02-17 | Compositions and methods for targeting type 1 interferon producing cells |
| AUPCT/AU2011/000155 | 2011-02-17 | ||
| PCT/AU2011/001056 WO2012021934A1 (en) | 2010-08-17 | 2011-08-17 | Humanized anti-interleukin 3 receptor alpha chain antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013268626A Division JP5933517B2 (ja) | 2010-08-17 | 2013-12-26 | ヒト化抗インターロイキン３レセプターα鎖抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013537418A JP2013537418A (ja) | 2013-10-03 |
| JP2013537418A5 true JP2013537418A5 (enExample) | 2013-11-14 |
| JP5524418B2 JP5524418B2 (ja) | 2014-06-18 |
Family
ID=45604615
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524306A Active JP5524418B2 (ja) | 2010-08-17 | 2011-08-17 | ヒト化抗インターロイキン３レセプターα鎖抗体 |
| JP2013268626A Active JP5933517B2 (ja) | 2010-08-17 | 2013-12-26 | ヒト化抗インターロイキン３レセプターα鎖抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013268626A Active JP5933517B2 (ja) | 2010-08-17 | 2013-12-26 | ヒト化抗インターロイキン３レセプターα鎖抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8569461B2 (enExample) |
| EP (2) | EP2606069B1 (enExample) |
| JP (2) | JP5524418B2 (enExample) |
| KR (1) | KR101347688B1 (enExample) |
| CN (1) | CN103025761B (enExample) |
| CA (1) | CA2805176C (enExample) |
| DK (1) | DK2606069T3 (enExample) |
| ES (1) | ES2506340T3 (enExample) |
| GB (1) | GB2488091B (enExample) |
| IL (1) | IL225631A (enExample) |
| NZ (1) | NZ604510A (enExample) |
| PL (1) | PL2606069T3 (enExample) |
| WO (1) | WO2012021934A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2730201C (en) * | 2008-07-10 | 2019-02-05 | Toray Industries, Inc. | Anti-cd179b antibody |
| US20100209341A1 (en) * | 2009-02-18 | 2010-08-19 | Csl Limited | Treatment of chronic inflammatory conditions |
| JP5694923B2 (ja) | 2009-04-27 | 2015-04-01 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体 |
| NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| ES2924722T3 (es) * | 2012-05-18 | 2022-10-10 | Aptevo Res & Development Llc | Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3 |
| WO2014138805A1 (en) * | 2013-03-14 | 2014-09-18 | Csl Limited | Anti il-3r alpha agents and uses thereof |
| WO2014138819A1 (en) * | 2013-03-14 | 2014-09-18 | Csl Limited | Agents that neutralize il-3 signaling and uses thereof |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| DK3189081T3 (da) * | 2014-09-05 | 2020-05-04 | Janssen Pharmaceutica Nv | Cd123-bindende midler og anvendelser deraf |
| EP3812398A3 (en) * | 2015-01-23 | 2021-07-21 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| TW201709932A (zh) * | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Ｃｄ１２３抗體及其共軛物 |
| AU2016282723B2 (en) | 2015-06-22 | 2021-09-23 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups |
| JP6768011B2 (ja) * | 2015-06-23 | 2020-10-14 | バイエル ファーマ アクチエンゲゼルシャフト | キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｃｄ１２３抗体との抗体薬物複合体 |
| SMT202100092T1 (it) * | 2015-06-29 | 2021-03-15 | Immunogen Inc | Anticorpi anti-cd123 e loro coniugati e derivati |
| JP7251981B2 (ja) | 2016-03-24 | 2023-04-04 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
| WO2017216028A1 (en) * | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| AU2017331256B2 (en) | 2016-09-21 | 2024-11-07 | Aptevo Research And Development Llc | CD123 binding proteins and related compositions and methods |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| CA3047491A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| KR102556826B1 (ko) | 2016-12-21 | 2023-07-18 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc) |
| PE20242042A1 (es) | 2017-06-02 | 2024-10-10 | Pfizer | Anticuerpos especificos para flt3 y sus usos |
| WO2019149637A1 (en) | 2018-01-31 | 2019-08-08 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| CN113874400B (zh) * | 2019-03-11 | 2025-02-07 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
| WO2020227071A1 (en) | 2019-05-04 | 2020-11-12 | Inhibrx, Inc. | Cd123-binding polypeptides and uses thereof |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| AU2021339754A1 (en) | 2020-09-11 | 2023-05-25 | Janssen Biotech, Inc. | Methods and compositions for modulating beta chain mediated immunity |
| AU2021414400A1 (en) | 2020-12-31 | 2023-08-17 | Innate Pharma | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| CA3224408A1 (en) * | 2021-08-06 | 2023-02-09 | Rosalba LEPORE | Discernible cell surface protein variants for use in cell therapy |
| CN119365495A (zh) | 2022-05-27 | 2025-01-24 | 赛诺菲 | 与NKp46和BCMA变体结合的具有Fc工程化的自然杀伤（NK）细胞接合物 |
| EP4296280A1 (en) * | 2022-06-21 | 2023-12-27 | F. Hoffmann-La Roche AG | Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs) |
| EP4619044A1 (en) | 2022-11-17 | 2025-09-24 | Hans-Georg Lerchen | Antibody-drug-conjugates cleavable in a tumor microenvironment |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0672068A4 (en) | 1992-09-25 | 1997-02-26 | Commw Scient Ind Res Org | TARGET MOLECULES BINDING POLYPEPTIDES. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US6177078B1 (en) * | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| DE69840412D1 (de) | 1997-10-31 | 2009-02-12 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| BRPI9910332B8 (pt) | 1998-05-06 | 2021-05-25 | Genentech Inc | método para purificação de um polipeptídio a partir de uma composição |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| PT1692182E (pt) | 2003-11-05 | 2010-05-13 | Roche Glycart Ag | Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| KR100627856B1 (ko) * | 2004-06-28 | 2006-09-25 | 에스케이 텔레콤주식회사 | 착신측 교환기를 이용하여 멀티미디어 링백톤 서비스를제공하는 방법 및 시스템 |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CN101098890B (zh) * | 2004-11-12 | 2012-07-18 | 赞科股份有限公司 | 对FcRn的结合被改变的Fc变体 |
| EP2388271A3 (en) | 2005-02-03 | 2012-08-01 | Antitope Limited | Human Antibodies and Proteins |
| US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
| JP2009504685A (ja) | 2005-08-15 | 2009-02-05 | アラーナ・テラピューティクス・リミテッド | 新世界霊長類フレームワーク領域を用いる設計された抗体 |
| CA2660795C (en) | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| EP2231187A4 (en) * | 2007-12-06 | 2013-02-20 | Csl Ltd | PROCESS FOR SUPPRESSING LEUKEMIA STEM CELLS |
| CA2736904A1 (en) * | 2008-09-26 | 2010-04-01 | Wyeth Llc | Compatible display vector systems |
| US20100209341A1 (en) * | 2009-02-18 | 2010-08-19 | Csl Limited | Treatment of chronic inflammatory conditions |
| JP5694923B2 (ja) * | 2009-04-27 | 2015-04-01 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体 |
| NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
-
2011
- 2011-06-07 NZ NZ604510A patent/NZ604510A/xx unknown
- 2011-08-17 WO PCT/AU2011/001056 patent/WO2012021934A1/en not_active Ceased
- 2011-08-17 DK DK11817577.7T patent/DK2606069T3/da active
- 2011-08-17 KR KR1020137002451A patent/KR101347688B1/ko active Active
- 2011-08-17 JP JP2013524306A patent/JP5524418B2/ja active Active
- 2011-08-17 ES ES11817577.7T patent/ES2506340T3/es active Active
- 2011-08-17 CA CA2805176A patent/CA2805176C/en active Active
- 2011-08-17 PL PL11817577T patent/PL2606069T3/pl unknown
- 2011-08-17 EP EP11817577.7A patent/EP2606069B1/en active Active
- 2011-08-17 US US13/256,926 patent/US8569461B2/en active Active
- 2011-08-17 EP EP14165984.7A patent/EP2778175B1/en active Active
- 2011-08-17 CN CN201180036658.2A patent/CN103025761B/zh active Active
- 2011-08-17 GB GB1211289.2A patent/GB2488091B/en active Active
-
2013
- 2013-04-08 IL IL225631A patent/IL225631A/en active IP Right Grant
- 2013-09-24 US US14/035,805 patent/US20140086912A1/en not_active Abandoned
- 2013-12-26 JP JP2013268626A patent/JP5933517B2/ja active Active
-
2015
- 2015-04-03 US US14/678,356 patent/US10047161B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014076062A5 (enExample) | ||
| US12448423B2 (en) | Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains | |
| Michailidou et al. | Allergic aspects of IgG4-related disease: implications for pathogenesis and therapy | |
| US20210171596A1 (en) | Untargeted and targeted il-10 fc-fusion proteins | |
| US20190070262A1 (en) | Interleukin-18 variants and methods of use | |
| JP2020513786A5 (enExample) | ||
| JP2009502171A5 (enExample) | ||
| JP2021524267A5 (enExample) | ||
| US20240374679A1 (en) | Interleukin-18 mimics and methods of use | |
| JP2021521784A (ja) | ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用 | |
| JP2009521909A5 (enExample) | ||
| JP2008542278A5 (enExample) | ||
| EP2970447B1 (en) | Pan-elr+ cxc chemokine antibodies | |
| AU2020283817A1 (en) | TIGIT and PD-1/TIGIT-binding molecules | |
| RU2015107889A (ru) | Композиция, содержащая два антитела, сконструированных так, чтобы они обладали пониженной и повышенной эффекторной функцией | |
| JP2010511388A5 (enExample) | ||
| CN115350275A (zh) | 抗pvrig抗体和使用方法 | |
| JP2015535691A5 (enExample) | ||
| US20160152699A1 (en) | Pan-elr+ cxc chemokine antibodies | |
| JP2012524524A5 (enExample) | ||
| IL322617A (en) | Engineered antibodies against IL-2 | |
| JP2021520393A5 (enExample) | ||
| CA3250092A1 (en) | CD3/BCMA/CD38 TRISACIFICAL ANTIBODIES | |
| TW202019965A (zh) | 治療多發性骨髓瘤之方法 | |
| JP2024509332A5 (enExample) |